Tumor-type agnostic, targeted therapies make a new step forward: The first tumor-agnostic approval o...
Tumor-type agnostic, targeted therapies make a new step forward: The first tumor-agnostic approval of a HER2-targeted therapy
About this item
Full title
Author / Creator
Publisher
Bosnia and Herzegovina: Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
Journal title
Language
English
Formats
Publication information
Publisher
Bosnia and Herzegovina: Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
Subjects
More information
Scope and Contents
Contents
Oncologic treatment has recently undergone substantial therapeutic paradigm shifts, from classical tumor-specific and biomarker-agnostic approaches to more molecular, biomarker-specific, and tumor-agnostic. Tumor-type (histology) agnostic drugs work across cancer types and present a novel shift in precision oncology. Compared with traditional cance...
Alternative Titles
Full title
Tumor-type agnostic, targeted therapies make a new step forward: The first tumor-agnostic approval of a HER2-targeted therapy
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_e3f3a473c5bb43eaa8f371c5848cfc3e
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e3f3a473c5bb43eaa8f371c5848cfc3e
Other Identifiers
ISSN
2831-0896,2831-090X
E-ISSN
2831-090X
DOI
10.17305/bb.2024.10641
